ARVN
|Arvinas Inc
NASDAQ
USD 7.83
+0.30|+3.98%
Current Price
USD 7.83
Change
+USD 0.30 (3.98%)
P/E Ratio
Dividend Yield
Market Cap
507.29M
Volume
3.51M
Open
USD 7.64
Previous Close
USD 7.53
52-Week High
USD 34.11
52-Week Low
USD 5.90
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. John G. Houston Ph.D.
Employees:430
Headquarters:New Haven, USA
Website:www.arvinas.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions